Datum | Källa | Rubrik | Typ | Alternativ |
---|---|---|---|---|
2023-11-20 | Penser Future | Penser Future: Luft under vingarna - Abliva | Pressreleaser | Visa Stäng |
|
||||
2023-11-17 | Abliva | Abliva AB Delårsrapport januari – september 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-11-17 | Abliva | Abliva AB Interim Report January – September 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-11-16 | Abliva | BioStock: Abliva tecknar globalt licensavtal för NeuroSTAT | Pressreleaser | Visa Stäng |
|
||||
2023-11-16 | Abliva | BioStock: Abliva signs global license deal for NeuroSTAT | Pressreleaser | Visa Stäng |
|
||||
2023-11-14 | Abliva | Abliva och Owl Therapeutics ingår licens- och samarbetsavtal för NeuroSTAT® vid traumatisk hjärnskada | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-14 | Abliva | Abliva and Owl Therapeutics enter into licensing and collaboration agreement for NeuroSTAT® in Traumatic Brain Injury | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-18 | Abliva | BioStock: Abliva's VP of Clinical Operations on the screening achievement | Pressreleaser | Visa Stäng |
|
||||
2023-10-18 | Abliva | BioStock: Ablivas VP of Clinical Operations om uppnått screening-mål | Pressreleaser | Visa Stäng |
|
||||
2023-10-11 | Abliva | Abliva når viktig milstolpe i den pågående FALCON-studien | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-19 | Abliva | BioStock:Abliva increases awareness of mitochondrial diseases | Pressreleaser | Visa Stäng |
|
||||
2023-09-19 | Abliva | BioStock:Abliva ökar medvetenheten om mitkondriella sjukdomar | Pressreleaser | Visa Stäng |
|
||||
2023-09-18 | Abliva | Abliva uppmärksammar World Mitochondrial Disease Week 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-18 | Abliva | Abliva to Participate in World Mitochondrial Disease Week 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-08 | Abliva | BioStock: Abliva erhåller FDA Fast Track-status | Pressreleaser | Visa Stäng |
|
||||
2023-09-08 | Abliva | BioStock: Abliva receives FDA Fast Track designation | Pressreleaser | Visa Stäng |
|
||||
2023-09-04 | Abliva | Ablivas huvudkandidat KL1333 får Fast Track-status från FDA | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-04 | Abliva | Abliva’s Lead Candidate KL1333 Receives FDA Fast Track Designation | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-21 | Penser Future | Penser Future: Patientrekrytering i fokus - Abliva | Pressreleaser | Visa Stäng |
|
||||
2023-08-18 | Abliva | Abliva AB Interim Report January – June 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-06-30 | Abliva | BioStock: First patient dosed in Abliva's Falcon study | Pressreleaser | Visa Stäng |
|
||||
2023-06-30 | Abliva | BioStock: Första patienten doserad i Ablivas Falcon-studie | Pressreleaser | Visa Stäng |
|
||||
2023-06-30 | Abliva | BioStock: Första patienten doserad i Ablivas Falcon-studie | Pressreleaser | Visa Stäng |
|
||||
2023-06-30 | Abliva | BioStock: First patient dosed in Abliva's Falcon study | Pressreleaser | Visa Stäng |
|
||||
2023-06-29 | Abliva | Abliva presenterar på UMDF Mitochondrial Medicine 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-29 | Abliva | Abliva presents at UMDF Mitochondrial Medicine 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-28 | Abliva | Abliva announces first patient dosed in the FALCON study | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-28 | Abliva | Abliva meddelar att första patienten doserats i FALCON-studien | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-14 | Abliva | BioStock: Ablivas CMO om presentation på Euromit | Pressreleaser | Visa Stäng |
|
||||
2023-06-14 | Abliva | BioStock: Abliva's presence is felt at Euromit | Pressreleaser | Visa Stäng |
|
||||
2023-06-12 | Abliva | Abliva presenterar vetenskapliga data vid internationell konferens inom mitokondriell medicin | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-12 | Abliva | Abliva presents scientific data at international conference on mitochondrial medicine | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-24 | Penser Future | Penser Future: Tidsplan för FALCON-studien intakt - Abliva | Pressreleaser | Visa Stäng |
|
||||
2023-05-24 | Penser Future | Penser Future: Interview with Abliva - Erik Penser Bank - May 24th 2023 | Pressreleaser | Visa Stäng |
|
||||
2023-05-23 | Abliva | Abliva AB Interim Report January – March 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-05-23 | Abliva | Abliva AB Delårsrapport januari-mars 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-05-04 | Abliva | Amendment of the Nomination Committee's proposal for Abliva’s Annual General Meeting in 2023 | Pressreleaser | Ladda ner | Visa Stäng |
Pressreleaser |
Amendment of the Nomination Committee’s proposal for Abliva’s Annual General Meeting in 2023
The notice for Abliva’s Annual General Meeting (AGM) 2023 was announced in a press release on April 4th, 2023. The Nominating Committee’s proposal for the election of Board members was presented in the press release. The Nomination Committee has now been informed that Dr. Edwin Moses is no longer available for re-election for personal reasons. David Laskow-Pooley has accepted re-election to the Board in addition to David Bejker, Jan Törnell, Denise Goode and Roger Franklin. The Nomination Committee proposes that David Laskow-Pooley is re-elected as Chair of the Board. The Nomination Committee also proposes a revised fee for the chairman of the board to be paid out at SEK 435,000 (400,000). Further, the Nomination Committee proposes a bonus payment in cash to David Laskow-Pooley of SEK 937,500. David Laskow-Pooley is required to use the full amount of the Bonus, net after income tax to acquire Abliva shares on the stock market. The company will pay the social security costs. The shares acquired for the Bonus will be locked in for a period of three (3) years after the acquisition. “We are pleased that David Laskow-Pooley will continue in his position as Chairman of the Board of Abliva and look forward to his leadership as the company continues the Phase 2 FALCON study evaluating the efficacy of KL1333 in patients with primary mitochondrial disease,” said Ingrid Teigland Akay, chair of the Nomination Committee. Information about existing Board members can be found on the company’s website www.abliva.com |
||||
2023-04-19 | Abliva | BioStock: FDA beviljar Ablivas NV354 särläkemedelsklassificering | Pressreleaser | Visa Stäng |
|
||||
2023-04-19 | Abliva | BioStock: FDA grants Abliva's NV354 Orphan Drug Designation | Pressreleaser | Visa Stäng |
|
||||
2023-04-17 | Abliva | Ablivas läkemedelskandidat NV354 beviljas särläkemedelsklassificering för behandling av mitokondriell sjukdom | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-17 | Abliva | Abliva’s Drug Candidate NV354 Granted Orphan Drug Designation for the Treatment of Mitochondrial Disease | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-04 | Abliva | Kallelse till årsstämma i Abliva AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-03-31 | Penser Future | Penser Future: Analytikerpresentation av Abliva - Erik Penser Bank - 31 mars 2023 | Pressreleaser | Visa Stäng |
|
||||
2023-03-31 | Abliva | Abliva AB publicerar årsredovisningen för 2022 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-03-24 | Penser Future | Penser Future: Nytt hopp för patienter med mitokondriella sjukdomar - Abliva | Pressreleaser | Visa Stäng |
|
||||
2023-03-22 | Abliva | BioStock: Abliva's CEO about the phase II study | Pressreleaser | Visa Stäng |
|
||||
2023-03-22 | Abliva | BioStock: Ablivas vd om fas II-studien | Pressreleaser | Visa Stäng |
|
||||
2023-03-16 | Abliva | BioStock Investor Meeting with Abliva | Pressreleaser | Visa Stäng |
|
||||
2023-03-08 | Abliva | Beslut vid extra bolagsstämma i Abliva AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-03-08 | Abliva | Resolutions at the Extraordinary General Meeting in Abliva AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-02-24 | Abliva | Abliva AB Bokslutskommuniké januari - december 2022 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-02-13 | Abliva | Ablivas valberedning föreslår Edwin Moses som ny styrelseledamot samt tillträdande ny styrelseordförande vid kommande bolagsstämmor | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-02-13 | Abliva | Abliva Nomination Committee to propose Edwin Moses as a new Board member and incoming Chair of the Board of Directors at upcoming General Meetings | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-02-10 | Abliva | BioStock: Abliva recruits Vice President of Clinical Operations | Pressreleaser | Visa Stäng |
|
||||
2023-02-10 | Abliva | BioStock: Abliva rekryterar Vice President of Clinical Operations | Pressreleaser | Visa Stäng |
|
||||
2023-02-09 | Abliva | Abliva tillkännager utfärdande av nytt amerikanskt patent för den terapeutiska substansen NV354 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-02-09 | Abliva | Abliva Announces Issuance of a New U.S. Patent for Therapeutic Compound NV354 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-02-01 | Abliva | Abliva utser Dag Nesse till Vice President of Clinical Operations | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-12-12 | Abliva | BioStock: Abliva startar klinisk studie i sen fas | Pressreleaser | Visa Stäng |
|
||||
2022-12-12 | Abliva | BioStock: Abliva starts late-stage study with KL1333 | Pressreleaser | Visa Stäng |
|
||||
2022-12-06 | Analysguiden | Analysguiden: ANALYS Abliva: FALCON drar igång | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-12-06 | Abliva | Abliva initiates the global FALCON study with lead candidate KL1333 | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-12-06 | Abliva | Abliva inleder den globala FALCON-studien med huvudkandidaten KL1333 | Analyser | Ladda ner | Visa Stäng |
|